Alexander Gieswinkel

Alexander Gieswinkel

Auto-generated profile, based on publicly available information

Alexander Gieswinkel

Preventive Cardiology and Preventive Medicine, Center for Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
DCDaniel Esteban Coral Candelo
Daniel Esteban Coral Candelo
FSFemke F. Smit
Femke F. Smit
AFAli Farzaneh
Ali Farzaneh
AGAlexander Gieswinkel
Alexander Gieswinkel
JTJuan Fernandez Tajes
Juan Fernandez Tajes
PFPaul W Franks
Paul W Franks
Obesity and cardiometabolic disease often, but not always, coincide. Distinguishing subpopulations within which cardiometabolic risk diverges from the risk expected for a given body mass index (BMI) may facilitate precision prevention of cardiometabolic diseases. Accordingly, we performed unsupervised clustering in four European population-based cohorts (N ≈ 173,000). We detected five discordant profiles consisting of individuals with cardiometabolic biomarkers higher or lower than expected given their BMI, which generally increases disease risk, in total representing ~20% of the total population. Persons with discordant profiles differed from concordant individuals in prevalence and future risk of major adverse cardiovascular events (MACE) and type 2 diabetes. Subtle BMI-discordances in biomarkers affected disease risk. For instance, a 10% higher probability of having a discordant lipid profile was associated with a 5% higher risk of MACE (hazard ratio in women 1.05, 95% confidence interval 1.03, 1.06, P = 4.19 × 10−10; hazard ratio in men 1.05, 95% confidence interval 1.04, 1.06, P = 9.33 × 10−14). Multivariate prediction models for MACE and type 2 diabetes performed better when incorporating discordant profile information (likelihood ratio test P < 0.001). This enhancement represents an additional net benefit of 4−15 additional correct interventions and 37−135 additional unnecessary interventions correctly avoided for every 10,000 individuals tested.

18 July 2024 in JHEP Reports
Verified
Journal Article
Open access
JBJoost Boeckmans
Joost Boeckmans
MMMaurice Michel
Maurice Michel
AGAlexander Gieswinkel
Alexander Gieswinkel
OTOliver Tüscher
Oliver Tüscher
SKStavros V. Konstantinides
Stavros V. Konstantinides
JSJörn M. Schattenberg
Jörn M. Schattenberg
Elevated liver stiffness has been associated with atrial fibrillation (AFib) in the general population. The mechanism underlying this association is unclear. Participants were recruited from the general population and prospectively enrolled with follow-up for 5 years. The fibrosis-4 (FIB-4) index was used as a surrogate marker for liver fibrosis. Proteomics analysis was performed using the 92-target Olink inflammation panel. Validation was performed using the NAFLD fibrosis score (NFS), aspartate aminotransferase to platelet index (APRI), and repeat confirmation proteomics. A sample of 11,509 participants with a mean age of 54.0 ± 11.1 years, 51.3% women, and a median FIB-4 index of 0.85 (0.65/1.12), was used. The FIB-4 index was predictive for prevalent (FIB-4 index adjusted odds ratio (aOR) per SD: 1.100 with 95% CI 1.011-1.196; p = 0.026), but not incident AFib (log[FIB-4 index]) adjusted hazard ratio: 1.125 with 95% CI 0.943-1.342, p = 0.19). Elastic net regularized regression identified CCL20, DNER, and CXCL10 for prevalent AFib, and AXIN1, CXCL10, and Flt3L for the log(FIB-4 index) (per SD) as most important in common regulated proteins. The relationship between the FIB-4 index, the identified proteins, and AFib was relevant and reproduced at the 5-year follow-up for CXCL10 after adjusting for confounders (log[FIB-4 index] per SD - CXCL10 [per SD] adjusted β 0.160 with 95% CI 0.127-0.194, p <0.0001; CXCL10 [per SD] - AFib aOR 1.455 with 95% CI 1.217-1.741, p <0.0001), reproduced using the NFS and APRI, and corresponding to increased serum levels. CXCL10 is linked to liver fibrosis, as determined by the FIB-4 index, and to prevalent AFib. How elevated liver stiffness relates to atrial fibrillation in the general population remains to be clarified. We hypothesized that systemic inflammation against a background of liver fibrosis produced from metabolic dysfunction-associated steatotic liver disease (MASLD), is involved in the pathophysiology of atrial fibrillation. Using large-scale targeted proteomics, we found that CXCL10 is related to both liver fibrosis, as defined by the fibrosis-4 index, and to atrial fibrillation. These results can aid evidence-based drug development for patients with atrial fibrillation and MASLD-related liver fibrosis.

22 December 2025 in Clinical Kidney Journal
Verified
Journal Article
Open access
DKDaniel Kraus
Daniel Kraus
AGAlexander Gieswinkel
Alexander Gieswinkel
SBSimone Cosima Boedecker-Lips
Simone Cosima Boedecker-Lips
PKPascal Klimpke
Pascal Klimpke
MSMarco Stortz
Marco Stortz
JWJulia Weinmann-Menke
Julia Weinmann-Menke
Background: Early diagnosis of chronic kidney disease (CKD) is essential to slow progression and delay or prevent dialysis. However, in the absence of specific symptoms, patients and physicians may remain unaware of the disease for a long period. Here we present an analysis from the Gutenberg Health Study, a prospective longitudinal cohort study, to estimate the prevalence of CKD indicators in the population. Methods: A representative sample of 10 125 individuals underwent extensive medical testing at baseline; 9331 were tested again after 5 years. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration formula with serum creatinine. Urinary albumin:creatinine ratios (UACRs) were determined from spot urine samples. Results: At baseline, 2.5% of subjects had decreased eGFR (30 mg/g) and 1.0% had both. Within 5 years, the incidence of new-onset decreased eGFR was 3.4%, the incidence of new-onset increased albuminuria was 6.9% and 1.4% had both new-onset decreased eGFR and increased albuminuria. Most importantly, 6.8% of all subjects and 3.2% of subjects without hypertension, diabetes or known kidney disease had chronic increased albuminuria, consistent with the presence of CKD. Conclusions: This is the first study to report the longitudinal prevalence of CKD in the population. Chronic increased albuminuria, a sensitive marker of CKD, is highly prevalent in the German population even in the absence of risk factors for kidney disease.

6 May 2025 in Circulation
Verified
Journal Article
Closed access
SBSimon Braumann
Simon Braumann
SMSascha Macherey-Meyer
Sascha Macherey-Meyer
APAmin Polzin
Amin Polzin
ACAngelika Costard-Jäckle
Angelika Costard-Jäckle
CMCaroline Morbach
Caroline Morbach
SBStephan Baldus
Stephan Baldus

24 July 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
GBGaukhar Baidildinova
Gaukhar Baidildinova
VCVincent Ten Cate
Vincent Ten Cate
MPMarina Panova-Noeva
Marina Panova-Noeva
BDBianca Dahlen
Bianca Dahlen
AGAlexander Gieswinkel
Alexander Gieswinkel
Kerstin JurkKerstin Jurk
Kerstin Jurk
Gaukhar Baidildinova, Vincent ten Cate, Marina Panova-Noeva, Bianca Dahlen, Alexander Gieswinkel, Saskia von Ungern-Sternberg, Steffen Rapp, Konstantin Str Gaukhar Baidildinova, Vincent ten Cate, Marina Panova-Noeva, Bianca Dahlen, Alexander Gieswinkel, Saskia von Ungern-Sternberg, Steffen Rapp, Konstantin Str

21 November 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
DCDaniel Esteban Coral Candelo
Daniel Esteban Coral Candelo
FSFemke F. Smit
Femke F. Smit
AFAli Farzaneh
Ali Farzaneh
AGAlexander Gieswinkel
Alexander Gieswinkel
JTJuan Fernandez Tajes
Juan Fernandez Tajes
PFPaul W Franks
Paul W Franks